In previous studies in ovarian8 cancer and CRC,9 where patients were treated with conventional cytotoxic chemotherapy supplemented by the anti-VEGF antibody, bevacizumab, we showed that plasma Tie2 (pTie2) was a response and progression biomarker for bevacizumab, Tie2 being the endothelial receptor for angiopoietin (Ang) 1 and 2, which promotes angiogenesis through Ang2–Tie2 and VEGF–VEGF receptor 2 axes. The gene discussed is TEK; the disease is colorectal carcinoma.